Lyme Disease Pipeline Assessment Report 2025: Emerging Therapeutics and Market Opportunities Revealed | DelveInsight

DelveInsight's "Lyme Disease Pipeline Insight 2025" report provides comprehensive insights about 7+ companies and 7+ pipeline drugs in the Lyme Disease pipeline landscape. It covers the Lyme Disease Pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Lyme Disease Pipeline Therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Curious about the latest updates in the Lyme Disease Pipeline? Click here to explore the therapies and trials making headlines @ Lyme Disease Pipeline Outlook Report [https://www.delveinsight.com/sample-request/lyme-disease-ld-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]

Key Takeaways from the Lyme Disease Pipeline Report

* On 29 September 2025, Pfizer conducted a clinical study is to evaluate a 6-valent OspA-based Lyme disease vaccine (VLA15) for prevention of Lyme disease within North America and Europe. Approximately 9,400 healthy participants (this number excludes participants from 8 sites which were terminated for quality issues) 5 years and older will be recruited from areas with high levels of endemic Lyme disease to receive VLA15 or placebo (an inactive substance consisting of saltwater). Each participant will have about a 50% chance of receiving VLA15 and about a 50% chance of receiving placebo.
* DelveInsight's Lyme Disease Pipeline report depicts a robust space with 7+ active players working to develop 7+ pipeline therapies for Lyme Disease treatment.
* The leading Lyme Disease Companies such as Valneva, Cortene, Blue Lake Biotechnology, Tarsus Pharmaceuticals, Inovio Pharmaceuticals, Aegis Life, Abzyme Therapeutics and others.
* Promising Lyme Disease Therapies such as TP-05, Amoxicillin, SHB001, VLA15, mRNA-1975, VLA15 , and others.

Want to know which companies are leading innovation in Lyme Disease? Dive into the full pipeline insights @ Lyme Disease Clinical Trials Assessment [https://www.delveinsight.com/sample-request/lyme-disease-ld-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]

The Lyme Disease Pipeline Report provides disease overview, pipeline scenario and therapeutic assessment of the key pipeline therapies in this domain. The Lyme Disease Pipeline Report also highlights the unmet needs with respect to the Lyme Disease.

Lyme Disease Overview

Lyme disease is the most common vector-borne disease in the United States. Lyme disease is caused by the bacterium Borrelia burgdorferi and rarely, Borrelia mayonii. It is transmitted to humans through the bite of infected blacklegged ticks. Typical symptoms include fever, headache, fatigue, and a characteristic skin rash called erythema migrans. If left untreated, infection can spread to joints, the heart, and the nervous system. Lyme disease is diagnosed based on symptoms, physical findings (e.g., rash), and the possibility of exposure to infected ticks. Laboratory testing is helpful if used correctly and performed with validated methods. Most cases of Lyme disease can be treated successfully with a few weeks of antibiotics. Steps to prevent Lyme disease include using insect repellent, removing ticks promptly, applying pesticides, and reducing tick habitat. The ticks that transmit Lyme disease can occasionally transmit other tickborne diseases as well.

Lyme Disease Emerging Drugs Profile

* VLA 15: Valneva

VLA15 is currently the only active vaccine program in clinical development against Lyme disease. VLA15 is a multivalent recombinant protein vaccine that targets six serotypes of Borrelia representing the most common pathogenic strains found in the United States and Europe. Valneva has completed recruitment and reported initial results for two Phase 2 clinical trials of VLA15 in over 800 healthy adults and in which Valneva observed high levels of antibodies against all six serotypes. Valneva announced a collaboration with Pfizer for late phase development and, if approved, commercialization of VLA15. As part of its collaboration with Pfizer, Valneva accelerated the pediatric development of VLA15 with an additional Phase 2 clinical trial initiated in March 2021. In July 2021, Pfizer and Valneva announced recruitment completion for VLA15-221 with a total of 625 participants, 5 to 65 years of age. The VLA15 program was granted Fast Track designation by the U.S. Food and Drug Administration (FDA) in July 2017

* CT38: Cortene

CT38 is a potent, short-lived, peptide agonist selective for CRFR2. It is comprised entirely of naturally-occurring amino acids. It was tested in animals and in healthy humans in a Phase 1 clinical trial. These studies have defined the safety profile of CT38 in humans and show that CT38 only lasts a few hours in the body.

If you're tracking ongoing Lyme Disease Clinical trials, this press release is a must-read. Tap to see the breakthroughs @ Lyme Disease Treatment Drugs [https://www.delveinsight.com/sample-request/lyme-disease-ld-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]

The Lyme Disease Pipeline report provides insights into:-

* The report provides detailed insights about companies that are developing therapies for the treatment of Lyme Disease with aggregate therapies developed by each company for the same.
* It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Lyme Disease Treatment.
* Lyme Disease Companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
* Lyme Disease Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
* Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Lyme Disease market.

Lyme Disease Companies

Valneva, Cortene, Blue Lake Biotechnology, Tarsus Pharmaceuticals, Inovio Pharmaceuticals, Aegis Life, Abzyme Therapeutics and others.

Lyme Disease Pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as,

* Oral
* Parenteral
* Intravenous
* Subcutaneous
* Topical

Lyme Disease Products have been categorized under various Molecule types such as,

* Monoclonal Antibody
* Peptides
* Polymer
* Small molecule
* Gene therapy

From emerging drug candidates to competitive intelligence, the Lyme Disease Pipeline Report covers it all - check it out now @ Lyme Disease Market Drivers and Barriers, and Future Perspectives [https://www.delveinsight.com/sample-request/lyme-disease-ld-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]

Scope of the Lyme Disease Pipeline Report

* Coverage- Global
* Lyme Disease Companies- Valneva, Cortene, Blue Lake Biotechnology, Tarsus Pharmaceuticals, Inovio Pharmaceuticals, Aegis Life, Abzyme Therapeutics and others.
* Lyme Disease Therapies- TP-05, Amoxicillin, SHB001, VLA15, mRNA-1975, VLA15 , and others.
* Lyme Disease Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
* Lyme Disease Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III

Stay ahead in Healthcare Research - discover what's next for the Lyme Disease Treatment landscape in this detailed analysis @ Lyme Disease Emerging Drugs and Major Players [https://www.delveinsight.com/sample-request/lyme-disease-ld-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]

Table of Contents

* Introduction
* Executive Summary
* Lyme Disease: Overview
* Pipeline Therapeutics
* Therapeutic Assessment
* Lyme Disease - DelveInsight's Analytical Perspective
* Late Stage Products (Phase III)
* VLA 15: Valneva
* Drug profiles in the detailed report.....
* Early Stage Products (Phase I)
* CT 38: Cortene
* Drug profiles in the detailed report.....
* Preclinical and Discovery Stage Products
* Lyme disease vaccine - Introvacc
* Drug profiles in the detailed report.....
* Inactive Products
* Lyme Disease Key Companies
* Lyme Disease Key Products
* Lyme Disease- Unmet Needs
* Lyme Disease- Market Drivers and Barriers
* Lyme Disease- Future Perspectives and Conclusion
* Lyme Disease Analyst Views
* Lyme Disease Key Companies
* Appendix

About Us

DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email:Send Email [https://www.abnewswire.com/email_contact_us.php?pr=lyme-disease-pipeline-assessment-report-2025-emerging-therapeutics-and-market-opportunities-revealed-delveinsight]
Phone: 09650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/report-store/lyme-disease-ld-pipeline-insight

Legal Disclaimer: Information contained on this page is provided by an independent third-party content provider. ABNewswire makes no warranties or responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you are affiliated with this article or have any complaints or copyright issues related to this article and would like it to be removed, please contact retract@swscontact.com



This release was published on openPR.